Tackling Global Antibiotic Resistance
Testing for multiple resistance genes
Since the accidental discovery of penicillin by Alexander Fleming in 1928, the world’s reliance on antibiotics has increased dramatically. Yet overuse and misuse across the world has seen antibiotics become ineffective against an increasingly large number of bacteria, and antibiotic resistance is now a globally ticking time bomb. Eurofins is at the forefront of efforts to tackle this crisis.
The Centers for Disease Control and Prevention reports that, each year, more than two million people in the US alone become infected with bacteria that are resistant to many antibiotics and attributes at least 23,000 deaths to these infections. Even the World Health Organization has warned that the world may be entering a ‘post antibiotic era’ in which some of the most dependable medicines become useless and common infections once again threaten to prove fatal.
Knowledge of the bacterial resistance genes is key. In 2016, Eurofins Diatherix launched the ABRx™ Antibiotic Resistance Panel, an exciting development that sees diagnostic tests able to simultaneously detect 17 clinically problematic and prevalent genes that lead to resistance to some of the most commonly prescribed antibiotics.
With specimens taken directly from the patient, the ABRx™ Antibiotic Resistance Panel provides rapid response results within one day. It also offers doctors and pharmacists clinically-important and accurate patient-specific information to aid their decision-making and ensure the prescription of an effective antibiotic in each clinical case.
Not only does this hinder the worsening of symptoms and hospital re-admissions, but detection results can be used to define an antibiotic class avoidance strategy. Best of all, the ABRx™ Panel tests are helping to slow the frightening pace of worldwide antibiotic resistance.
The science behind
The ABRx™ Antibiotic Resistance Panel allows the molecular identification of antibioticresistant genes in patient samples. It is focused on the detection of 17 gene types, within seven gene classes which are associated with resistance to three major groups of antibiotics (ß-lactams like penicillins, cephalosporins and carbapenems, fluoroquinolones, and macrolides). Offering the direct detection of clinical samples, without the requirement for bacterial isolation, the ABRx™ Panel has been validated on respiratory secretions, rectal/stool swabs, and urine specimens.